Validation Data Gallery
|Positive WB detected in||Ramos cells|
|Positive IP detected in||Raji cells|
|Positive IHC detected in||human lymphoma tissue, human colon cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HeLa cells|
|Positive FC detected in||Jurkat cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Immunofluorescence (IF)||IF : 1:10-1:100|
|Sample-dependent, check data in validation data gallery|
The immunogen of 25027-1-AP is RELB Fusion Protein expressed in E. coli.
|Tested Reactivity||human, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||RELB fusion protein Ag13824|
|Full Name||v-rel reticuloendotheliosis viral oncogene homolog B|
|Calculated molecular weight||62 kDa|
|Observed molecular weight||62-65 kDa|
|GenBank accession number||BC028013|
|Gene ID (NCBI)||5971|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
RELB, also named as Transcription factor RelB, is a 579 amino acid protein, which contains one RHD domain. RELB localizes in the nucleus and cytoplasm. RELB is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis.
|Product Specific Protocols|
|WB protocol for RELB antibody 25027-1-AP||Download protocol|
|IHC protocol for RELB antibody 25027-1-AP||Download protocol|
|IF protocol for RELB antibody 25027-1-AP||Download protocol|
|IP protocol for RELB antibody 25027-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.
Cell Death Dis
Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma.
J Clin Endocrinol Metab
Circulating Myeloid-derived Suppressor Cells Facilitate Invasion of Thyroid Cancer Cells by Repressing miR-486-3p.